Specific Diagnostics: Scott Wehage

Specific Diagnostics has appointed Scott Wehage the company's director of US clinical trials. He was previously clinical project manager for Becton Dickinson's global clinical development department and oversaw clinical trials for device and in vitro diagnostic product development. Prior to that, he was a program manager at Johns Hopkins University. Based in Mountain View, California, Specific Dx has developed an IVD system leveraging a metabolomic signature technology that allows for the detection and identification of microorganisms as they grow in culture. The first commercial application of the technology will be for the determination of antibiotic susceptibility.